Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Repros initiates phase IIb comparative study of Androxal and Testim for male fertility

July 3, 2008

FDA grants DuoCort orphan drug designation for adrenal insufficiency

July 3, 2008

ARISE trial data, mechanism of action study reported for AGI-1067

July 3, 2008

Caloric intake reduced with AC-2307 in obese subjects

July 3, 2008

Novel DPP-IV inhibitor profiled at LG Life Sciences

July 2, 2008

Novartis Pharma initiates phase I study of oral PTH-134 in postmenopausal osteoporosis

July 2, 2008

Indevus receives FDA approvable letter for Nebido

July 2, 2008

Recent patents describe novel antidiabetic agents

July 1, 2008

Affymax initiates enrollment in phase II Hematide trial

July 1, 2008

New agents for endocrine-associated disorders disclosed in recent patents

June 30, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...